

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis - Phase 1|Phase 2 - Not yet recruiting

**Code:** NCT06159725    **Year:** 2023    **Date:** December 2023

**Author:** Clarametix Biosciences, Inc.

### Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

### Participants

Persistent Infection|Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

### Interventions

Drug: CMTX-101|Drug: Placebo

### Outcome measures

ss the AUC<sub>0-∞</sub> Area under the concentration time curve from zero to infinite time following a single IV infusion of CMTX-101|Assess the Terminal phase elimination rate determined by ELISA following a single IV infusion of CMTX-101|Assess the Terminal elimination half- determined by ELISA following a single IV infusion of CMTX-101|Assess the Apparent total body clearance (CL/F) determined by ELISA following a single IV infusion of CMTX-101|Assess the Apparent volume distribution (V<sub>x</sub>/F) determined by ELISA following a single IV infusion of CMTX-101|Evaluate the immunogenicity of CMTX-101 as measured by anti-drug antibodies (ADA) determined by the electrochemiluminescence assay following a single IV infusion of CMTX-101|Assess the apparent reduction in pulmonary P. auginosa burden as measured by quantitative microbial culture of sputum

<https://ClinicalTrials.gov/show/NCT06159725>

### Keywords

CMTX-101; monoclonal antibodies; Anti-Bacterial Agents; pharmacological\_intervention;